A surprisingly high percentage (11.5%) of cases harboring DUOXA2 mutations in this borderline CH cohort suggests that mutations in this gene may be more significant in the etiology of CH than previously anticipated. The gene discussed is DUOXA2; the disease is cyclic hematopoiesis.